MAFLD is defined as hepatic steatosis with metabolic dysregulation, type 2 diabetes mellitus, overweight or obesity, and is characterized by extensive liver lesions, which can progress from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and even HCC
Per one study, doses of about 50100 mg/kg/day are generally well tolerated
2 Semaglutide, liraglutide, and tirzepatide have all shown cardiovascular protective effects, such as reducing lipid and blood pressure levels
Use consistently for at least 812 weeks to allow the supplement to build up and assess effectiveness
Diarrhea or constipation Headaches Stomach discomfort Most side effects tend to improve over time as your body adjusts to the medication
A baseline reading was taken for 1 minute, followed by a 5-minute recording period with 100 nM exendin-4